Free Newsletter
Adaptive trial network expands south
Argentinean CRO KLIXAR has signed onto Health Decisions' Agile Clinical Network for adaptive trial design. As a network member, KLIXAR will be able to tap best practices information and partnership opportunities.
The CRO was trained in Agile Clinical Development techniques for adaptive trial operations as a prerequisite to network membership. KLIXAR also gets access to Health Decisions' data management systems, biostatistics expertise, medical writers, advanced data collection tools and real-time reporting capabilities.
Adaptive trials, meanwhile, are showing signs of beginning a migration from the theoretical to the real world. A Phase II study involving Alkermes's candidate treatment for alcohol dependence--a multi-center, double-blind, placebo-controlled 12-week effort involving some 440 subjects--has an adaptive design that allows for analysis after 40 percent of subjects are on the treatment for eight weeks.
- here's the Health Decisions announcement
- see the Alkermes announcement
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
